Skin cancer: surgery and treatment options

Surgery for melanoma aims to remove the cancer completely. Mohs surgery combines removal of skin cancer with microscopic examination of the tissue edges during the operation. For invasive melanoma, Mohs and wide local excision have both been studied, but they cannot simply be treated as interchangeable options. Special tissue stains used during Mohs or staged excision have also been studied for invasive melanoma; their use was associated with less cancer returning at the treated site than examination with routine stains alone.

The discussion depends on the particular cancer, rather than on the name of the operation alone. For melanoma, tumour characteristics, location and effects on function matter when considering how much surrounding tissue to remove. In studies of invasive melanoma, people treated with Mohs were generally older and had thinner tumours than those treated with wide local excision. For basal cell and squamous cell skin cancers at stages T1–T2 without lymph-node involvement, research has compared surgery with external-beam radiation and brachytherapy, a form of radiation treatment. These are different treatment discussions from melanoma surgery, not evidence that radiation can replace surgery for every skin cancer.

For basal cell and squamous cell skin cancers at stages T1–T2 without lymph-node involvement, a 2019 review included 21,371 patients across the treatment groups. At one year, pooled rates of cancer returning at the treated site were 0.8% after conventional excision and 0.2% after Mohs surgery. These are pooled study estimates, not a direct comparison of otherwise identical patients; the review found similar local cancer control across surgery and radiation treatments at one year. A 2026 review of nonmelanoma skin cancer instead found lower local recurrence after Mohs than after superficial radiation, but this does not establish the same comparison at the same one-year time point.

For melanoma, earlier reviews reported less local recurrence after Mohs or staged excision than after wide local excision. A 2025 review focused on invasive melanoma found that differences between patients and overlapping study populations prevented a reliable conclusion about which operation gives better outcomes for comparable tumours. A lower recurrence estimate in one group therefore does not by itself show that the operation is better for an individual patient.

Cancer can return at the treated site after surgery. Examination of tissue during Mohs can also reveal an unexpected finding, sometimes another tumour, that changes the need for further treatment. Pain medicines have their own risks: even a short postoperative opioid prescription can lead to dependence.

Pain relief after Mohs surgery and reconstruction does not automatically require an opioid prescription. In a 2021 consensus study involving 23 Mohs surgeons, the panel recommended against routinely prescribing opioids to every patient. For melanoma, a sentinel lymph-node biopsy is a staging procedure used to assess the disease; it is a separate consideration from removal of the skin tumour.